Seattle’s HDT Bio raises $3M seed (updated to $6M) to fund replicating-RNA COVID-19 vaccine HDT-301 and clinical trials

Seattle biotech HDT Bio raised about $3 million in seed funding to advance its replicating RNA COVID-19 vaccine candidate HDT-301 and hire staff with clinical trial experience; the company reported promising preclinical results and plans human trials beginning in Brazil this month with U.S. and India trials possible later in the year. An update notes an additional $3 million raised, bringing the round to $6 million led by Zoic Capital to support three products entering clinical trials.

UUniversity of Washington